SNDX vs. PTGX, AMPH, DYN, ENTA, JAZZ, BPMC, IONS, OGN, BBIO, and CYTK
Should you be buying Syndax Pharmaceuticals stock or one of its competitors? The main competitors of Syndax Pharmaceuticals include Protagonist Therapeutics (PTGX), Amphastar Pharmaceuticals (AMPH), Dyne Therapeutics (DYN), Enanta Pharmaceuticals (ENTA), Jazz Pharmaceuticals (JAZZ), Blueprint Medicines (BPMC), Ionis Pharmaceuticals (IONS), Organon & Co. (OGN), BridgeBio Pharma (BBIO), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical preparations" industry.
Protagonist Therapeutics (NASDAQ:PTGX) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, community ranking, risk and earnings.
Protagonist Therapeutics has a beta of 2.09, suggesting that its share price is 109% more volatile than the S&P 500. Comparatively, Syndax Pharmaceuticals has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500.
In the previous week, Protagonist Therapeutics and Protagonist Therapeutics both had 4 articles in the media. Protagonist Therapeutics' average media sentiment score of 1.47 beat Syndax Pharmaceuticals' score of 0.71 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media.
98.6% of Protagonist Therapeutics shares are held by institutional investors. 5.4% of Protagonist Therapeutics shares are held by company insiders. Comparatively, 4.1% of Syndax Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Protagonist Therapeutics has higher earnings, but lower revenue than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.
Syndax Pharmaceuticals' return on equity of 43.42% beat Protagonist Therapeutics' return on equity.
Protagonist Therapeutics presently has a consensus target price of $38.00, indicating a potential upside of 34.99%. Syndax Pharmaceuticals has a consensus target price of $34.42, indicating a potential upside of 78.60%. Given Protagonist Therapeutics' higher possible upside, analysts clearly believe Syndax Pharmaceuticals is more favorable than Protagonist Therapeutics.
Syndax Pharmaceuticals received 107 more outperform votes than Protagonist Therapeutics when rated by MarketBeat users. Likewise, 64.79% of users gave Syndax Pharmaceuticals an outperform vote while only 59.73% of users gave Protagonist Therapeutics an outperform vote.
Summary
Protagonist Therapeutics beats Syndax Pharmaceuticals on 10 of the 16 factors compared between the two stocks.
Get Syndax Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SNDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Syndax Pharmaceuticals Competitors List
Related Companies and Tools
